Tofacitinib

Especificaciones

477600-75-2Número CAS

689-145-4Número CE

3-[(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrileNombre IUPAC

C16H20N6OFórmula química

312.37 g/molPeso molecular

Tofacitinib; 477600-75-2; Tasocitinib; 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile; CP-690550; CP 690550; Cp-690 free base; tofacitinibum; 3-{(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}-3-oxopropanenitrile; CP690550; 87LA6FU830; CP-690550 FREE BASE; CP-690,550 FREE BASE; CP690,550; CP-690-550; CHEBI:71200; DTXSID90197271; CP-690; 3-((3R,4R)-4-Methyl-3-(methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile; 3-[(3R,4R)-4-methyl-3-[methyl({7H-pyrrolo[2,3-d]pyrimidin-4-yl})amino]piperidin-1-yl]-3-oxopropanenitrile; 3-[(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile; 3-Piperidinamine, 1-(cyanoacetyl)-4-methyl-N-methyl-N-1H-pyrrolo(2,3-d)pyrimidin-4-yl-, (3R,4R)-; 3-((3R,4R)-4-methyl-3-(methyl((7H-pyrrolo(2,3-d)pyrimidin-4-yl))amino)piperidin-1-yl)-3-oxopropanenitrile; RefChem:6313; JAK inhibitors: tofacitinib; DTXCID00119762; L04AA29; 689-145-4; 1259404-17-5; Tofacitinib (CP-690550,Tasocitinib); 3-((3R,4R)-rel-4-Methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile; rac-Tofacitinib; Tofacitinib (CP-690550); Tofacitinib [USAN]; C16H20N6O; CHEMBL221959; 1-Piperidinepropanenitrile, 4-methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-beta-oxo-, (3R,4R)-; racemic-tofacitinib; racemic-Tasocitinib; MFCD22628813; Tofacitinib (USAN); MFCD11035919; 3-[(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-1-piperidyl]-3-oxo-propanenitrile; 3-{(3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile; (+)-TOFACITINIB; Tofacitinib [USAN:INN]; UNII-87LA6FU830; Tofacitinib?; Tofacitinib Base; 3eyg; 3fup; 3lxk; 4oti; (Rac)-Tofacitinib; 1-PIPERIDINEPROPANENITRILE, 4-METHYL-3-(METHYL-7H-PYRROLO(2,3-D)PYRIMIDIN-4-YLAMINO)-.BETA.-OXO-, (3R,4R)-; 1-Piperidinepropanenitrile, 4-methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-.beta.-oxo-, (3R,4R)-; 3-(4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile; MI1; 477600-75-2 (free base); Tofacitinib (Standard); TOFACITINIB [MI]; TOFACITINIB [INN]; TOFACITINIB [VANDF]; PFE-PKIS 25; PFE-PKIS_25; TOFACITINIB [WHO-DD]; SCHEMBL322753; GTPL5677; orb1224990; orb1300872; SCHEMBL29351183; HSDB 8311; EX-A205; UJLAWZDWDVHWOW-YPMHNXCESA-N; GLXC-90307; BDBM50193995; EBC-11351; HY-40354R; NSC782351; NSC800953; AKOS005145814; AKOS005258733; AC-8193; AT43433; CCG-264998; CS-0050; DB08895; FT32555; GS-6106; NSC-782351; NSC-800953; SDCCGSBI-0654407.P002; TOFACITINIB (CONTROLLED RELEASE); NCGC00229511-02; NCGC00229511-04; NCGC00229511-10; NCGC00229511-24; NCGC00229511-25; NCGC00244463-01; 3-[(3R*,4R*)-4-Methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile; HY-40354; NS00069315; T6321; CP- 690 550; D09970; AB01565786_02; EN300-1718468; AR-270/43507983; F050788; Q3530324; BRD-K31283835-001-01-9; BRD-K31283835-048-04-4; (3R,4R)-3-{4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile; (3R,4R)-4-methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-beta-oxo-1-piperidine propanenitrile; (3R,4R)-4-Methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-beta-oxo-1-piperidine-propanenitrile; 1-Piperidinepropanenitrile, 4-methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-|A-oxo-, (3R,4R)-; 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile citrate; 3-{(3R,4R)-4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]piperidin-1-yl}-3-oxo-propionitrile; 3-{(3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile; 3-{4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-1-piperidinyl}-3-oxopropanenitrile; REL-3-((3R,4R)-4-METHYL-3-(METHYL(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)AMINO)PIPERIDIN-1-YL)-3-OXOPROPANENITRILESinónimos